|
|
||||||||
Departments of Medicinal Chemistry and Chemistry, Purdue University, West Lafayette, Indiana
Mallinckrodt Medical, Inc., St. Louis, Missouri
Correspondence: For correspondence or reprints contact: Mark A. Green, PhD, Department of Medicinal Chemistry, Pharmacy Building, Purdue University, West Lafayette, IN 47907.
ABSTRACT
Gallium-67 and 68>Ga complexes have been synthesized with tripodal hexadentate salicylaldimine ligands derived from 1.1,1-tris(salicylaldiminomethyl)ethane, sal3tame. The four ligands evaluated contained alkoxy substituents (n-BuO-, iso-BuO-, sec-BuO-, and n-PrO-) on the terminal ethane carbon of the ligand backbone. In the case of the n-PrO-derivative, the tris(salicylaldimine) ligand was additionally substituted with methoxy groups in the 5-position of the aromatic rings. The 67Ga and 68Ga-complexes of these ligands were prepared by ligand exchange from 67Ga-or 68Ga-acetylacetonate in ethanol. The nonradioactive Ga[(sal)3tame-O-iso-Bu] complex was similarly prepared and shown by x-ray crystallography to exhibit the expected pseudo-octahedral N3O33- coordination sphere about the Ga3+ center. These Ga-radiotracers are highly lipophilic, as demonstrated by their octanol/water partition coefficients. Log P values of 3.1, 3.1, 2.6, and 2.5 were found for the [(sal)3tame-O-iso-Bu},[(sal)3tame-O-n-Bu], [(sal)3tame-O-sec-Bu], and [(5-MeOsal)3tame-O-n-Pr] complexes, respectively. Following intravenous injection into rats, these complexes are rapidly cleared from the blood and exhibit significant myocardial uptake. At 1 min postinjection, 2.4%, 2.0%, 2.1% and 1.1% of the injected dose was found in the heart for the iso-BuO, n-BuO, sec-BuO, and n-PrO complexes, respectively, dropping to 1.0%, 0.8%, 0.8%, and 0.7% at 5 min. The corresponding heart-to-blood ratios are quite high: 17 ± 3, 14 ± 2, 12 ± 2 and 3.5 ± 0.4 at 1 min and 14 ± 4, 10 ± 1, 10 ± 1 and 3.2 ± 0.1 at 5 min postinjection. High quality myocardial images were obtained with PET in a normal dog using data collected from 2 to 10 min following intravenous injection of 68Ga[(sal)3tame-O-iso-Bu].
This article has been cited by other articles:
![]() |
G. L. Griffiths, C.-H. Chang, W. J. McBride, E. A. Rossi, A. Sheerin, G. R. Tejada, H. Karacay, R. M. Sharkey, I. D. Horak, H. J. Hansen, et al. Reagents and Methods for PET Using Bispecific Antibody Pretargeting and 68Ga-Radiolabeled Bivalent Hapten-Peptide-Chelate Conjugates J. Nucl. Med., January 1, 2004; 45(1): 30 - 39. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |